{
  "meta": {
    "title": "Oncologic_Emergencies_Cup",
    "url": "https://brainandscalpel.vercel.app/oncologic-emergencies-cup-9ad63d55.html",
    "scrapedAt": "2025-11-29T18:24:59.198Z"
  },
  "questions": [
    {
      "id": 19789,
      "choices": [
        {
          "id": 79117,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presence of hypotension</span></span></span></p>"
        },
        {
          "id": 79118,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">History of chronic obstructive pulmonary disease (COPD)</span></span></span></p>"
        },
        {
          "id": 79119,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No dehydration requiring intravenous fluids</span></span></span></p>"
        },
        {
          "id": 79120,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fever of unknown origin without localizing signs or symptoms</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman with breast cancer is undergoing adjuvant chemotherapy. Three days after her most recent cycle, she presents to the emergency department with a fever of 38.7&deg;C (101.7&deg;F) and generalized weakness. Her past medical history is significant for hypertension, well-controlled with medication. On examination, she appears fatigued but is otherwise stable. Laboratory tests reveal an absolute neutrophil count (ANC) of 500 cells/&micro;L, confirming neutropenia. Given her presentation with fever and neutropenia, the emergency department team considers her risk of complications using the Multinational Association for Supportive Care in Cancer (MASCC) risk index to guide her management. Based on the MASCC risk index for febrile neutropenia, which of the following factors would categorize this patient as low risk?</span></span></span></p>",
      "unique_key": "Q2862613",
      "question_audio": null,
      "question_video": null,
      "map_id": 19700,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) No dehydration requiring intravenous fluids</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Multinational Association for Supportive Care in Cancer (MASCC) risk index score is a tool used to identify febrile neutropenia patients at low risk of complications, who may be suitable for outpatient management. Factors that contribute to a higher score (indicating lower risk) include stable vital signs, no dehydration, outpatient status at the onset of fever, absence of chronic obstructive pulmonary disease (COPD), solid tumor or hematologic malignancy with no previous fungal infection, and no recent hospitalization. Specifically, &quot;No dehydration requiring intravenous fluids&quot; is a factor that would categorize a patient as low risk according to the MASCC risk index.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Presence of hypotension would categorize a patient as high risk, as it indicates hemodynamic instability, which is a serious complication of febrile neutropenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>B.</strong> A history of chronic obstructive pulmonary disease (COPD) would also place a patient in a higher risk category, as underlying lung disease can complicate the management of febrile neutropenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D.</strong> Fever of unknown origin without localizing signs or symptoms could apply to many cases of febrile neutropenia and, by itself, does not necessarily categorize a patient as low risk according to the MASCC risk index. Other factors, such as the patient&#39;s overall clinical stability, presence of comorbidities, and intensity of the chemotherapy regimen, also need to be considered.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The MASCC risk index is used to identify febrile neutropenia patients who are at low risk for complications and might be suitable for outpatient management. Factors that indicate lower risk include stable vital signs, no significant comorbidities like COPD, and no dehydration requiring intravenous fluids.</span></span></span></p>",
      "correct_choice_id": 79119,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19790,
      "choices": [
        {
          "id": 79121,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Febrile neutropenia </span></span></span></p>"
        },
        {
          "id": 79122,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumor-related fever </span></span></span></p>"
        },
        {
          "id": 79123,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Central line-associated bloodstream infection (CLABSI) </span></span></span></p>"
        },
        {
          "id": 79124,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pneumonia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 67-year-old man with metastatic lung cancer on chemotherapy develops fever, chills, and tenderness with purulent discharge at his PICC line site. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4736378",
      "question_audio": null,
      "question_video": null,
      "map_id": 19701,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) CLABSI</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of fever, chills, and local signs of infection at the PICC line site strongly suggests a central line-associated bloodstream infection (CLABSI).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Febrile neutropenia:</span></strong><span style=\"font-size:12.0pt\"> While this patient likely has neutropenia due to chemotherapy, the local signs of infection at the PICC line point more specifically towards CLABSI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tumor-related fever:</span></strong><span style=\"font-size:12.0pt\"> This is less likely in the presence of clear signs of infection at the catheter site.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pneumonia:</span></strong><span style=\"font-size:12.0pt\"> While possible, the absence of respiratory symptoms and the presence of local signs of infection at the catheter site make CLABSI more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong><span style=\"font-size:12.0pt\"> CLABSI is a serious complication of central venous catheters. Prompt recognition and treatment are essential to prevent morbidity and mortality.</span></span></span></p>",
      "correct_choice_id": 79123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19791,
      "choices": [
        {
          "id": 79125,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Muscle strain </span></span></span></p>"
        },
        {
          "id": 79126,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Osteoarthritis </span></span></span></p>"
        },
        {
          "id": 79127,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metastatic spinal cord compression </span></span></span></p>"
        },
        {
          "id": 79128,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lumbar disc herniation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with a known history of prostate cancer presents to your clinic complaining of severe back pain that has been progressively worsening over the past few weeks. The pain is particularly intense at night, making it difficult for him to sleep, and it does not improve with rest. Which of the following is the MOST likely diagnosis?</span></span></span></p>",
      "unique_key": "Q6344135",
      "question_audio": null,
      "question_video": null,
      "map_id": 19702,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Metastatic spinal cord compression (MSCC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s age, history of prostate cancer, and the characteristic nature of the back pain (worse at night, unrelieved by rest) strongly suggest metastatic spinal cord compression (MSCC). Prostate cancer has a propensity to metastasize to the bone, and spinal metastases can compress the spinal cord or nerve roots, leading to pain and neurological symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Muscle strain:</span></strong><span style=\"font-size:12.0pt\"> Muscle strain typically presents with localized pain that worsens with movement and improves with rest. It&#39;s less likely to be severe at night or associated with a history of cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Osteoarthritis:</span></strong><span style=\"font-size:12.0pt\"> Osteoarthritis is a degenerative joint disease that can cause back pain, but it&#39;s usually associated with stiffness and pain that worsens with activity and improves with rest. The patient&#39;s age and cancer history make MSCC more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lumbar disc herniation:</span></strong><span style=\"font-size:12.0pt\"> While a herniated disc can cause severe back pain, it&#39;s often associated with radicular pain (shooting pain down the leg) and neurological deficits. The patient&#39;s presentation and cancer history are more consistent with MSCC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Back pain in a patient with a history of cancer, especially if it&#39;s worse at night or unrelieved by rest, warrants prompt evaluation for possible MSCC. Early diagnosis and treatment are critical to prevent neurological complications.</span></span></span></p>",
      "correct_choice_id": 79127,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19792,
      "choices": [
        {
          "id": 79129,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Plain X-ray of the spine </span></span></span></p>"
        },
        {
          "id": 79130,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent intravenous dexamethasone </span></span></span></p>"
        },
        {
          "id": 79131,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Whole spine MRI </span></span></span></p>"
        },
        {
          "id": 79132,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Surgical decompression</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old man with a history of lung cancer presents with severe back pain and weakness in his legs. Neurological examination reveals decreased lower extremity strength and hyperreflexia. What is the MOST appropriate initial management step?</span></span></span></p>",
      "unique_key": "Q3105699",
      "question_audio": null,
      "question_video": null,
      "map_id": 19703,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Urgent intravenous dexamethasone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has back pain and abnormal neurological findings, suggesting MSCC. In this scenario, urgent administration of high-dose dexamethasone is crucial to reduce spinal cord edema and prevent further neurological deterioration. MRI is also indicated, but dexamethasone should be given first to avoid delays in treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Plain X-ray of the spine:</span></strong><span style=\"font-size:12.0pt\"> While plain X-rays can sometimes show bony destruction suggestive of metastases, they are not sensitive enough to visualize the spinal cord or nerve roots, which are crucial for assessing the extent of compression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Whole spine MRI:</span></strong><span style=\"font-size:12.0pt\"> MRI is the gold standard for diagnosing MSCC, but it should not delay the administration of dexamethasone, which is crucial to prevent further neurological deterioration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Surgical decompression:</span></strong><span style=\"font-size:12.0pt\"> While surgery may be indicated in some cases of MSCC, it is not the initial management step. High-dose dexamethasone should be given first to reduce spinal cord edema and stabilize the patient before considering surgical intervention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong><span style=\"font-size:12.0pt\"> In patients with suspected MSCC and neurological deficits, urgent high-dose dexamethasone is the priority to reduce spinal cord edema and prevent further neurological damage.</span></span></span></p>",
      "correct_choice_id": 79130,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19788,
      "choices": [
        {
          "id": 79113,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Appendicitis </span></span></span></p>"
        },
        {
          "id": 79114,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diverticulitis </span></span></span></p>"
        },
        {
          "id": 79115,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neutropenic enterocolitis (typhlitis)</span></span></span></p>"
        },
        {
          "id": 79116,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemic colitis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old man with acute myeloid leukemia (AML) undergoing chemotherapy presents to the emergency department with a 2-day history of fever, right lower quadrant abdominal pain, and watery diarrhea. His absolute neutrophil count (ANC) is 300/&micro;L. Abdominal CT scan reveals cecal wall thickening. Which of the following is the MOST likely diagnosis?</span></span></span></p>",
      "unique_key": "Q5572605",
      "question_audio": null,
      "question_video": null,
      "map_id": 19699,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Neutropenic enterocolitis (typhlitis)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of neutropenia, fever, right lower quadrant abdominal pain, diarrhea, and cecal wall thickening on imaging is highly suggestive of typhilitis, (aka. neutropenic enterocolitis). This is a serious complication of neutropenia, where the bowel wall becomes inflamed and can potentially perforate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Appendicitis:</span></strong><span style=\"font-size:12.0pt\"> While appendicitis can present with similar symptoms, it is less likely in this patient with neutropenia and cecal wall thickening.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Diverticulitis:</span></strong><span style=\"font-size:12.0pt\"> Diverticulitis typically affects the left colon and is less common in younger individuals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ischemic colitis:</span></strong><span style=\"font-size:12.0pt\"> Ischemic colitis is more common in older individuals with cardiovascular risk factors. It usually presents with bloody diarrhea and is less likely in the context of neutropenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neutropenic enterocolitis is a life-threatening complication that can occur in patients with severe neutropenia. Early recognition and prompt treatment are essential.</span></span></span></p>",
      "correct_choice_id": 79115,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53422,
      "choices": [
        {
          "id": 213169,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hyperkalemia </span></span></span></p>"
        },
        {
          "id": 213170,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hyperuricemia </span></span></span></p>"
        },
        {
          "id": 213171,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hyperphosphatemia </span></span></span></p>"
        },
        {
          "id": 213172,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hypercalcemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old male with Burkitt&#39;s lymphoma is undergoing chemotherapy. Three days after starting treatment, he presents with fatigue, muscle cramps, and nausea. Lab results show:</span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium: 6.2 mEq/L</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uric acid: 9.0 mg/dL</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phosphate: 5.5 mg/dL</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium: 9.5 mg/dL</span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following electrolyte abnormalities found in this patient is NOT a criterion for the diagnosis of Laboratory Tumor Lysis Syndrome (LTLS)?</span></span></span></p>",
      "unique_key": "Q9102153",
      "question_audio": null,
      "question_video": null,
      "map_id": 25226,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hypercalcemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laboratory Tumor Lysis Syndrome (LTLS) is characterized by a specific constellation of electrolyte abnormalities that result from the rapid breakdown of tumor cells. The criteria for LTLS, as reflected in the patient&#39;s case, include:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperkalemia (K+ &ge; 6 mEq/L)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hyperuricemia (uric acid &ge; 8 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperphosphatemia (PO4 &ge; 4.5 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypocalcemia (Ca2+ &le; 7 mg/dL) OR a 25% decrease from baseline</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient in this vignette demonstrates hyperkalemia, hyperuricemia, and hyperphosphatemia, fulfilling the criteria for LTLS. His calcium level is within the normal range, so hypercalcemia is NOT a part of the diagnostic criteria for LTLS in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hyperkalemia:</span></strong><span style=\"font-size:12.0pt\"> This is a defining feature of LTLS, as the breakdown of tumor cells releases intracellular potassium into the bloodstream.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hyperuricemia:</span></strong><span style=\"font-size:12.0pt\"> Tumor cell lysis releases nucleic acids, which are metabolized to uric acid, leading to hyperuricemia in LTLS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hyperphosphatemia:</span></strong><span style=\"font-size:12.0pt\"> The breakdown of tumor cells also releases intracellular phosphate, contributing to hyperphosphatemia in LTLS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LTLS is a potentially life-threatening oncologic emergency characterized by specific electrolyte abnormalities: hyperkalemia, hyperuricemia, hyperphosphatemia, and sometimes hypocalcemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">CTLS (&ge; 1) </span></em></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">(Clinical criteria for TLS)<em>: </em></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">AKI, arrhythmias, Sz, symptomatic hypocalcemia</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prompt recognition and management of LTLS are critical to prevent complications like acute kidney injury, cardiac arrhythmias, and seizures.</span></span></li>\r\n</ul>",
      "correct_choice_id": 213172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53423,
      "choices": [
        {
          "id": 213173,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low risk </span></span></span></p>"
        },
        {
          "id": 213174,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intermediate risk </span></span></span></p>"
        },
        {
          "id": 213175,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High risk </span></span></span></p>"
        },
        {
          "id": 213176,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cannot be determined</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old male presents to your clinic with a rapidly growing neck mass that has caused him discomfort over the past few weeks. He also reports feeling fatigued and has lost some weight recently. On examination, you palpate a large, firm, non-tender lymph node in his left cervical region. A biopsy of the lymph node reveals Burkitt lymphoma. Further workup shows his lactate dehydrogenase (LDH) level is 3 times the upper limit of normal. Considering his diagnosis and laboratory findings, which Tumor Lysis Syndrome (TLS) risk category does this patient fall into?</span></span></span></p>",
      "unique_key": "Q2049561",
      "question_audio": null,
      "question_video": null,
      "map_id": 25227,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) High risk</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Burkitt lymphoma is a highly aggressive B-cell lymphoma with a rapid growth rate. The presence of a rapidly enlarging lymph node and a significantly elevated LDH level (3 times the upper limit of normal) places this patient in the high-risk category for TLS. High-risk patients are more likely to experience severe complications from TLS, such as acute kidney injury, cardiac arrhythmias, and even death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Low risk:</span></strong><span style=\"font-size:12.0pt\"> Low-risk malignancies generally have a slower growth rate and lower tumor burden, making TLS less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intermediate risk:</span></strong><span style=\"font-size:12.0pt\"> Intermediate-risk malignancies have a moderate risk of TLS, often based on specific tumor characteristics or laboratory findings. In this case, the patient&#39;s elevated LDH level and rapid tumor growth place him in the high-risk category.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cannot be determined:</span></strong><span style=\"font-size:12.0pt\"> The information provided is sufficient to determine the patient&#39;s TLS risk category.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Burkitt lymphoma is a high-risk malignancy for TLS, especially when associated with elevated LDH levels.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with high-risk TLS require aggressive preventive measures, including intensive hydration and uric acid-lowering therapy, to minimize the risk of complications.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 213175,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53424,
      "choices": [
        {
          "id": 213177,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute heart failure</span></span></span></p>"
        },
        {
          "id": 213178,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Superior vena cava (SVC) syndrome</span></span></span></p>"
        },
        {
          "id": 213179,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary embolism</span></span></span></p>"
        },
        {
          "id": 213180,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Constrictive pericarditis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 64-year-old man presents to the emergency department with progressive swelling of his face and neck over the past two weeks. He also reports increasing breathlessness, especially when lying flat, and a feeling of fullness in his head. His medical history is significant for a 40-pack-year smoking history, although he quit smoking 10 years ago. On examination, his face appears plethoric, and there is evident distension of the veins in his neck and chest. Additionally, he exhibits mild cyanosis of the upper body and swelling of the arms. A chest X-ray reveals a mass in the right upper mediastinum. Based on the patient&#39;s presentation and history, which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q2608490",
      "question_audio": null,
      "question_video": null,
      "map_id": 25228,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Superior vena cava (SVC) syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation with progressive swelling of the face and neck, breathlessness, plethoric facial appearance, distended neck and chest veins, and cyanosis of the upper body, along with a mediastinal mass on chest X-ray, is highly suggestive of Superior Vena Cava (SVC) syndrome. SVC syndrome occurs when there is obstruction of the SVC, leading to impaired venous return from the head, neck, and upper extremities to the heart. This can cause the symptoms noted above. The presence of a mediastinal mass in a patient with a significant smoking history raises concern for a malignancy such as lung cancer, which is a common cause of SVC syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A.</strong> Acute heart failure can cause facial and upper extremity swelling due to fluid overload, but it is less likely to present with the pronounced venous distension and plethoric face that are characteristic of SVC syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>C.</strong> Pulmonary embolism typically presents with acute shortness of breath, chest pain, and possibly hemoptysis, but not with the venous distension and facial swelling seen in SVC syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D.</strong> Constrictive pericarditis can cause symptoms of venous congestion due to impaired cardiac filling, but it usually presents with generalized edema, ascites, and elevated jugular venous pressure, rather than the localized swelling of the face and neck and the specific venous distension seen in SVC syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Superior vena cava (SVC) syndrome is characterized by obstruction of the SVC, leading to impaired venous return from the head, neck, and upper extremities. Symptoms include facial and upper extremity swelling, plethoric facial appearance, distended neck and chest veins, and cyanosis of the upper body. A mediastinal mass, especially in patients with a significant smoking history, raises suspicion for an underlying malignancy such as lung cancer as a cause of SVC syndrome.</span></span></span></p>",
      "correct_choice_id": 213178,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53425,
      "choices": [
        {
          "id": 213181,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Small cell lung cancer (SCLC) </span></span></span></p>"
        },
        {
          "id": 213182,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-small cell lung cancer (NSCLC) </span></span></span></p>"
        },
        {
          "id": 213183,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphoma </span></span></span></p>"
        },
        {
          "id": 213184,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metastatic breast cancer</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with a history of smoking presents with facial swelling, distended neck veins, and shortness of breath. Chest X-ray shows a large right lung mass. Which of the following malignancies is the MOST likely cause of this patient&#39;s diagnosis?</span></span></span></p>",
      "unique_key": "Q8592019",
      "question_audio": null,
      "question_video": null,
      "map_id": 25229,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>B) Non-small cell lung cancer (NSCLC)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of the patient&#39;s smoking history, lung mass on chest X-ray, and symptoms of facial swelling, distended neck veins, and shortness of breath strongly suggests superior vena cava (SVC) syndrome.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common cause of SVC syndrome is lung cancer, and among lung cancers, non-small cell lung cancer (NSCLC) is more frequently associated with SVC syndrome than small cell lung cancer (SCLC).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Small cell lung cancer (SCLC):</span></strong><span style=\"font-size:12.0pt\"> While SCLC can also cause SVC syndrome, it is less common than NSCLC as a cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lymphoma:</span></strong><span style=\"font-size:12.0pt\"> Lymphoma can sometimes cause SVC syndrome, but it is less frequent than lung cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metastatic breast cancer:</span></strong><span style=\"font-size:12.0pt\"> While metastatic breast cancer can spread to the mediastinum and cause SVC syndrome, it&#39;s less common than primary lung cancer as a cause in this clinical scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SVC syndrome is a medical emergency caused by obstruction of the superior vena cava, leading to impaired venous return from the head, neck, and upper extremities.</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung cancer, particularly NSCLC, is the most common cause of SVC syndrome.</span></span></li>\r\n</ul>",
      "correct_choice_id": 213182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53426,
      "choices": [
        {
          "id": 213185,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CK7 positive, CK20 negative, TTF-1 negative </span></span></span></p>"
        },
        {
          "id": 213186,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CK7 negative, CK20 positive, CDX2 positive </span></span></span></p>"
        },
        {
          "id": 213187,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CK7 positive, TTF-1 positive, Napsin A positive </span></span></span></p>"
        },
        {
          "id": 213188,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ER positive, PR positive, HER2 negative</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old woman presents with weight loss, fatigue, and a left supraclavicular lymph node. Biopsy reveals metastatic adenocarcinoma. Extensive imaging fails to identify a primary tumor site. Immunohistochemistry (IHC) is ordered to help determine the origin of the malignancy. Which IHC staining pattern would MOST STRONGLY suggest a gastrointestinal (GI) primary?</span></span></span></p>",
      "unique_key": "Q5134057",
      "question_audio": null,
      "question_video": null,
      "map_id": 25230,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) CK7 negative, CK20 positive, CDX2 positive</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This IHC pattern is highly suggestive of a GI origin, particularly colorectal adenocarcinoma. CK20 is a cytokeratin predominantly expressed in epithelial cells of the GI tract, and CDX2 is a transcription factor involved in intestinal development and differentiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CK7 positive, CK20 negative, TTF-1 negative:</span></strong><span style=\"font-size:12.0pt\"> This pattern is more suggestive of lung or breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. CK7 positive, TTF-1 positive, Napsin A positive:</span></strong><span style=\"font-size:12.0pt\"> This pattern is strongly indicative of lung adenocarcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ER positive, PR positive, HER2 negative:</span></strong><span style=\"font-size:12.0pt\"> This pattern is typically seen in breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> IHC staining can aid in identifying the primary site in cancers of unknown primary (CUP), guiding further management and treatment decisions.</span></span></p>",
      "correct_choice_id": 213186,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53427,
      "choices": [
        {
          "id": 213189,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TTF-1 </span></span></span></p>"
        },
        {
          "id": 213190,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CDX2 </span></span></span></p>"
        },
        {
          "id": 213191,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S-100 </span></span></span></p>"
        },
        {
          "id": 213192,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ER</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old woman Non-smoker presents to your clinic with a persistent cough and recent episodes of coughing up blood (hemoptysis). Chest X-ray reveals a suspicious lung mass. A biopsy is performed, and you suspect lung adenocarcinoma based on the initial histopathology. Which of the following immunohistochemical (IHC) markers would be MOST helpful in confirming this diagnosis?</span></span></span></p>",
      "unique_key": "Q9097560",
      "question_audio": null,
      "question_video": null,
      "map_id": 25231,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>A) TTF-1</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Even though the patient is a non-smoker, TTF-1 (Thyroid Transcription Factor-1) remains the most helpful IHC marker for confirming the diagnosis of lung adenocarcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">TTF-1</span></strong><span style=\"font-size:12.0pt\"> is a nuclear transcription factor highly expressed in lung and thyroid tissues. It is a sensitive and specific marker for lung adenocarcinoma, aiding in its distinction from other lung cancers or metastases, regardless of smoking history.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CDX2:</span></strong><span style=\"font-size:12.0pt\"> CDX2 is a marker of intestinal differentiation and is typically used to identify cancers of gastrointestinal origin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. S-100:</span></strong><span style=\"font-size:12.0pt\"> S-100 is a marker for melanomas and neural crest-derived tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ER (Estrogen Receptor):</span></strong><span style=\"font-size:12.0pt\"> ER is a hormone receptor that is primarily used in the context of breast cancer. While some lung adenocarcinomas can be ER-positive, it&#39;s not a specific or sensitive marker for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While smoking is a major risk factor for lung cancer, adenocarcinoma can occur in non-smokers as well.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TTF-1 remains a valuable IHC marker for confirming the diagnosis of lung adenocarcinoma, regardless of smoking history.</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IHC staining can aid in differentiating between various types of lung cancer and metastases, which is critical for guiding treatment decisions.</span></span></li>\r\n</ul>",
      "correct_choice_id": 213189,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53428,
      "choices": [
        {
          "id": 213193,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum and 5-FU</span></span></span></p>"
        },
        {
          "id": 213194,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pembrolizumab</span></span></span></p>"
        },
        {
          "id": 213195,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum and etoposide</span></span></span></p>"
        },
        {
          "id": 213196,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Palliative care with a focus on symptom management</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old woman presents with metastatic adenocarcinoma of unknown primary origin. Imaging and biopsy have failed to identify the primary site. What is the most appropriate initial approach to the treatment of her cancer?</span></span></span></p>",
      "unique_key": "Q4737180",
      "question_audio": null,
      "question_video": null,
      "map_id": 25232,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Platinum and 5-FU</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cases of metastatic adenocarcinoma of unknown primary origin (CUP - Cancer of Unknown Primary), treatment often involves empiric chemotherapy regimens aimed at controlling the disease and alleviating symptoms, given the absence of a known primary site to guide more targeted therapy. A combination of platinum-based chemotherapy (such as cisplatin or carboplatin) and 5-fluorouracil (5-FU) is a common choice for empiric treatment in patients with CUP, particularly for adenocarcinomas. This regimen has demonstrated efficacy in various adenocarcinomas and is often used when the primary site cannot be identified.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>B.</strong> Pembrolizumab, a PD-1 inhibitor, has shown promise in certain types of cancers, particularly those with high levels of microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). While it represents an exciting advancement in cancer therapy, pembrolizumab would typically be considered in the context of CUP after specific testing for MSI-H or dMMR, or PD-L1 expression, rather than as an initial empiric treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>C.</strong> Platinum and etoposide are often used together in the treatment of small cell lung cancer and other neuroendocrine tumors, but without evidence of a neuroendocrine component, this regimen would not be the first choice for an adenocarcinoma of unknown primary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D.</strong> While palliative care and symptom management are crucial aspects of cancer treatment, especially in advanced disease, they are not typically the initial approach for a patient who may still benefit from systemic therapy aimed at controlling the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with metastatic adenocarcinoma of unknown primary origin, an empiric chemotherapy regimen that includes a platinum agent (cisplatin or carboplatin) and 5-fluorouracil (5-FU) is often used as the initial treatment approach, aiming to control the disease and alleviate symptoms.</span></span></span></p>",
      "correct_choice_id": 213193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53429,
      "choices": [
        {
          "id": 213197,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Single, small axillary node involvement</span></span></span></p>"
        },
        {
          "id": 213198,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenocarcinoma</span></span></span></p>"
        },
        {
          "id": 213199,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated serum tumor markers with a single site of metastasis</span></span></span></p>"
        },
        {
          "id": 213200,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Absence of liver metastasis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 54-year-old woman presents to the oncology clinic with a 3-month history of unexplained weight loss, night sweats, and a palpable mass in her left axilla. A comprehensive workup, including mammography, abdominal CT, PET scan, and colonoscopy, fails to identify a primary tumor site. Biopsy of the axillary mass reveals adenocarcinoma. Which of the following features is considered unfavorable in the prognosis of cancer of unknown primary?</span></span></span></p>",
      "unique_key": "Q7100274",
      "question_audio": null,
      "question_video": null,
      "map_id": 25233,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Adenocarcinoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In cancers of unknown primary (CUP), certain histological subtypes and clinical features are associated with the prognosis. Adenocarcinoma, when presenting as CUP, is generally considered to have an unfavorable prognosis compared to certain other subtypes, such as squamous cell carcinoma confined to lymph nodes (especially cervical) or certain well-defined subsets of CUP with favorable prognoses (like women with axillary nodal metastases resembling breast cancer or men with blastic bone metastases resembling prostate cancer). Adenocarcinoma as CUP often indicates widespread disease and may respond less favorably to empirical chemotherapy regimens compared to more well-defined, treatable primary cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>A.</strong> Single, small axillary node involvement, especially in women, can sometimes be managed similarly to breast cancer, with a relatively better prognosis than other forms of CUP. This is often considered a subset with a favorable prognosis if it resembles breast cancer histologically and clinically.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>C.</strong> Elevated serum tumor markers with a single site of metastasis could influence prognosis, depending on the specific context and markers involved. However, this alone does not universally signify an unfavorable prognosis without considering other clinical and histopathological features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>D.</strong> The absence of liver metastasis is generally a favorable prognostic sign in CUP. Liver involvement is often associated with a more aggressive disease course and a poorer prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the context of cancer of unknown primary (CUP), adenocarcinoma histology is generally considered to have an unfavorable prognosis compared to other subsets of CUP that may have more defined treatment approaches and better outcomes, such as squamous cell carcinoma confined to lymph nodes or women with axillary nodal metastases resembling breast cancer</span></span></span></p>",
      "correct_choice_id": 213198,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}